Pfizer Lowers Annual Revenue Expectations, Implying layoffs
胡胡胡美丽_ss
发表于 2023-10-15 10:12:35
291
0
0
[Pfizer cuts its annual revenue forecast, implying layoffs] According to a Reuters report on the 14th local time, the US biopharmaceutical company Pfizer cut its annual revenue forecast by about 13% on the 13th, because its sales of COVID-19 vaccines and therapeutic drugs were lower than expected. At present, it is expected that the company's revenue will be between $58 billion and $61 billion in 2023, lower than the previous forecast of $67 billion to $70 billion. In addition, the company also stated that it will cut costs, with a goal of saving at least $3.5 billion by the end of 2024. The measures include layoffs, but Pfizer did not provide details on the number of layoffs or areas of layoffs.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- Hesai Technology's Q3 revenue increased by 21.1% year-on-year
- Shangde Institution's third quarter revenue and profit continue to decline, and fancy marketing is unable to turn things around
- Zhiwen Group's net revenue for Q3 2024 was 2.6747 billion yuan, with a net profit of 493.3 million yuan
- Oracle's quarterly revenue and profit both increased
- The ninth one! Broadcom joins trillion dollar club, AI revenue doubles
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- Micron Technology's revenue outlook falls short of analysts' expectations, causing its stock price to plummet by approximately 18% after market hours
- Micron Technology's revenue outlook falls short of analysts' expectations, causing its stock price to plummet by approximately 18% after market hours
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy